摘要
目的探讨多发性骨髓瘤(MM)患者血清β2-微球蛋白(β2-MG)测定的临床意义。方法采用酶联免疫吸附试验法测定血清标本中的β2-MG值。结果MM初发组β2-MG为(6131±2770)μg/L,明显高于对照组β2-MG(2540±908)μg/L,差异有统计学意义(P<0.05)。MM治疗有效组β2-MG(3150±1920)μg/L与MM初发组β2-MG(6131±2770)μg/L相比较,β2-MG明显下降,差异有统计学意义(P<0.05)。结论血清β2-MG可作为MM患者预后及疗效判断的指标。
Objective To explore the clinical signifieanee of serum measurement of β2-microglobulin in patients with multiple myeloma （MM）. Methods ELISA were used to detect the levels of β2-microglobulin in serum specimens. Results The level of β2-microglobulin in preliminary-diagnosed patients with multiple myeloma was significantly higher than that in healthy controls （P〈0.05）. The level of β2-microglobulin in multiple myeloma patients with better therapeutic effect was significantly lower than that in preliminary-diagnosed patients with multiple myeloma （P〈0.05）. Conclusion β2-microglobulin may be used as an indicator of evaluation of therapeutic effect and prognosis of multiple myeloma.
出处
《检验医学与临床》
CAS
2009年第4期252-252,共1页
Laboratory Medicine and Clinic
